HER2/neu Protein News and Research

RSS

HER2/neu is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast and ovarian. Cancer cells removed from the body may be tested for the presence of HER2/neu to help decide the best type of treatment. HER2/neu is a type of receptor tyrosine kinase. Also called c-erbB-2, human EGF receptor 2, and human epidermal growth factor receptor 2.

Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging

Iron oxide nanoparticles have shown promise as agents for detecting tumors using magnetic resonance imaging (MRI), but such efforts have been limited by the relatively weak magnetic signal generated by these nanoparticles.

22 Jan 2007

Nanoparticles yield delivery tools for therapeutic nucleic acids

Cancer researchers hold great hope that nucleic acid-based therapeutics, such as anticancer genes, antisense oligonucleotides, and small interfering RNA (siRNA) molecules, will prove to be powerful antitumor agents.

16 Jan 2007

Gene amplification could guide treatment for high-risk breast cancer

A new study shows that breast cancer patients with an "amplification," or greater number of copies, of the TOP2A gene are 45% more likely than women who do not have this amplification to benefit from a longer course of anthracycline-based adjuvant chemotherapy.

11 May 2006

New test for detecting small amounts of proteins in the blood

Researchers at the University of Pennsylvania School of Medicine have developed a paradigm-shifting method for detecting small amounts of proteins in the blood.

13 Mar 2006

Discovery establishes a role for the gene Rsf-1 in ovarian cancer

Johns Hopkins Kimmel Cancer Center researchers have linked alterations in a gene, called Rsf-1, to the most deadly ovarian cancers. The scientists say the discovery is the first to establish a role for the gene in ovarian cancer and may lead to a test that can predict, early on, which patients will develop aggressive disease.

3 Oct 2005

Cancer vaccine based on the bacterium Listeria monocytogenes, can cure mice with breast tumors

A team from the University of Pennsylvania School of Medicine has shown that by using a cancer vaccine based on the bacterium Listeria monocytogenes, they can cure mice with established breast tumors. Cancer vaccines, which are more properly described as immunotherapy, work by boosting an immune response against tumor-associated antigens.

27 Sep 2005

Snail, a molecule normally important in embryonic development, can promote breast cancer recurrence

Using a recently developed mouse model of breast cancer, a team from the University of Pennsylvania School of Medicine has shown that Snail, a molecule normally important in embryonic development, can promote breast cancer recurrence.

20 Sep 2005

Gene that regulates normal embryonic development is found at high levels in virtually all forms of breast cancer

A gene that appears to help regulate normal embryonic development is found at high levels in virtually all forms of breast cancer, according to a new study led by Laszlo Radvanyi, Ph.D., associate professor of breast and melanoma medical oncology at The University of Texas M. D. Anderson Cancer Center.

25 Jul 2005

Novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some breast cancers

Based on successful animal studies, a novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some human breast cancers, say researchers at The University of Texas M. D. Anderson Cancer Center.

10 Jan 2005

Strategic analysis of the breast cancer therapeutics pipeline

Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.

15 Jul 2004

Cancer drug gefitinib (Iressa) may be able to restore tamoxifen's anticancer activity

A new study has found a possible mechanism for tamoxifen resistance in breast cancer and provides evidence that another cancer drug--gefitinib (Iressa)--may be able to restore tamoxifen's anticancer activity.

15 Jun 2004

Drug combo effective for advanced breast cancer

A pair of studies at UCLA's Jonsson Cancer Center that takes laboratory science to the patients' bedside found that combining the molecularly targeted therapy Herceptin with a specific chemotherapy combination resulted in significant tumor response rates and longer relapse-free periods in women with an aggressive form of advanced breast cancer.

19 May 2004